Bhakti Dwivedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bhakti Dwivedi has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Adam I. Marcus
Department of Hematology and Medical Oncology, Emory University, Atlanta, USA
29 shared publications - Melissa Gilbert-Ross
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, USA
29 shared publications - Chang-Soo Seong
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia
28 shared publications - Rebecca E. Parker
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia
28 shared publications - Amy Herrera
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia
26 shared publications - Ashok Reddy Dinasarapu
Department of Neurology, Emory University School of Medicine , Atlanta, GA 30322
26 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Legends for Supplementary Figures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Legends for Supplementary Figures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S5 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S5 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S3 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S3 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
List of upregulated transcripts in KL vs. KP invasive spheroids with respect to K>C.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
List of upregulated transcripts in KL vs. KP invasive spheroids with respect to K>C.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Invasive phenotyping of K, KL, and KP HBECs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Invasive phenotyping of K, KL, and KP HBECs
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Invasive phenotyping of K, KL, and KP HBECs
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Invasive phenotyping of K, KL, and KP HBECs